Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models

Cancer Immunology, Immunotherapy

Volumn 62, Issue 6, 2013, Pages 1011-1019

  Patel, Sandip Pravin ^a   Bristol, Andrew ^b   Saric, Olga ^b   Wang, Xue Ping ^b   Dubeykovskiy, Alex ^b   Arlen, Philip M ^b   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department Precision Biologics   (United States)

Author keywords

Colorectal cancer; Monoclonal antibody; MUC5AC related; NPC 1C; Pancreatic cancer; Tumor vaccine

Indexed keywords

ENSITUXIMAB; IMMUNOGLOBULIN G; MUCIN 5AC; PROTEIN VARIANT; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; CROSS REACTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MUCIN 5AC; NEOPLASMS; PANCREATIC NEOPLASMS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878884646     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1420-z     Document Type: Article

References (21)

1. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825
2. Jimeno A, Hidalgo M (2006) Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 5(4):787-796
3. Laheru D, Jaffee EM (2005) Immunotherapy for pancreatic cancer science driving clinical progress. Nat Rev Cancer 5(6):459-467
4. Hollinshead AC, McWright CG, Alford TC, Glew DH, Gold P, Herbeman RB (1972) Separation of skin reactive intestinal cancer antigen from the carcinoembryonic antigen of gold. Science 177(52):887-889
5. Hollinshead A, Elias EG, Arlen M, Buda B, Mosley M, Scherrer J (1985) Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer 56(3):480-489
6. Luka J, Arlen PM, Bristol A (2011) Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC. J Biomed Biotechnol 2011. Article ID 934757. doi: 10.1155/2011/934757
7. Qi CF, Nieroda C, De Filippi R, Greiner JW, Correale P, Schlom J, Tsang KY (1995) Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells. Immunol Lett 47(1):15-24
8. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040-2048
9. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658-1664
10. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
11. Lau SK, Weiss LM, Chu PG (2004) Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122:61-69
12. Baldus SE, Engelmann K, Hanisch FG (2004) MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41:189-231
13. O'Donnell R, Breen D, Wilson S, Djukanovic R (2006) Inflammatory cells in the airways in COPD. Thorax 61(5):448-454
14. Kim GE, Bae HI, Park HU et al (2002) Aberrant expression of MUC5AC and MUC6 gastric mucins and sialylated antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 123:1052-1060
15. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly expressed genes in pancreatic ductal adenocarcinomas A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614-8622
16. Byrd JC, Bresalier RS (2004) Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 23:77-99
17. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC (2001) The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001(91):1973-1982
18. Khodarev N et al (2009) MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 69:2833-2837
19. Chen Y et al (2007) Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 67:4924-4932
20. Hagenbeek A (2011) VIII. Radioimmunotherapy in malignant lymphoma: an underused tool? Ann Oncol 22(suppl 4):iv51-iv53
21. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783-1791